Cadila Healthcare (also known as Zydus Cadila) said that it has secured tentative approval from the US Food and Drug Administration (FDA) to market Brivaracetam Tablets in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg. Brivaracetam is approved for the treatment of partial-onset of seizures (epilepsy). Zydus Cadila will […]
Cadila Healthcare (also known as Zydus Cadila) said that it has adopted a new technology initiative called ‘Zydus Verify’ to protect patients against counterfeit drugs. In this connection, the Indian pharma company has rolled out a new feature in the packaging of its critical drugs for helping patients in identifying whether the product is genuine […]
Cadila Healthcare (also known as Zydus Cadila) said that it has secured final approval from the US Food and Drug Administration (FDA) to market Fluphenazine Hydrochloride Tablets 1 mg, 2.5 mg, 5 mg, and 10 mg. The reference listed drug (RLD) of Zydus Cadila’ Fluphenazine Hydrochloride Tablets is Prolixin Tablets, which are indicated for the […]
Cadila Healthcare (also known as Zydus Cadila) has signed a license supply and commercialization agreement with Taiwanese pharma company TLC to commercialize the latter’s Black Fungus drug – AmphoTLC (Amphotericin B Liposome for Injection 50mg) in India. As per the terms of the deal, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to […]
Zydus Cadila has secured restricted emergency use approval for ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) from the Drug Controller General of India (DCGI) for the treatment of moderate Covid-19 infection in adult patients. According to the Indian pharma company, a single dose subcutaneous regimen of Virafin will make the treatment more easier for the patients. When […]